Tumor Microenvironment: T Cell Exclusion
Physical Barriers and ECM Remodeling | Soluble Factors | Aberrant Chemokine Signaling | Metabolic Barriers | Stromal and Tumor Inhibitory Immune Checkpoints | Suppressive Cell Populations | Dysfunctional Vasculature | Featured Resources
T cell exclusion is a key mechanism in tumor progression, leading to "cold" tumors that lack effector T cell infiltration and impair effective anti-tumor immunity. In the absence of cytotoxic CD8⁺ T cells within the tumor core, immune surveillance is diminished, resulting in lower levels of critical cytokines such as IFN-γ that are essential for activating other immune effectors.
This exclusion is mediated by physical barriers like dense stroma and aberrant vasculature, as well as immunosuppressive factors (e.g., TGF-β, VEGF) and suppressive cells (Tregs, MDSCs, TAMs), which together establish a tumor microenvironment (TME) hostile to T cell entry and function. Consequently, these cold tumors evade immune detection, resist checkpoint inhibitor therapies, and grow unchecked.
In contrast, "hot” tumors, which are rich in infiltrating, activated T cells, display robust immune engagement, producing pro-inflammatory signals and generally responding better to immunotherapy. Therefore, overcoming T cell exclusion and converting cold tumors into hot tumors is a major focus in cancer immunotherapy research, aiming to improve treatment efficacy and patient responses.
We provide a comprehensive portfolio of validated antibodies, small molecule modulators, recombinant proteins, and sensitive ELISA kits to help advance our understanding of the complex factors driving T cell exclusion. Our tools enable detailed analysis of molecular pathways and cellular interactions in the tumor microenvironment, accelerating discoveries and therapeutic development.
Comparison of the Immunological Features in Cold vs. Hot Tumors
Characteristics of Cold Tumors | Characteristics of Hot Tumors |
| Lack of effector T cell infiltration within the tumor core (immune excluded) or near complete absence of T cells (immune desert) | High infiltration of immune cells, especially cytotoxic CD8+ T cells, present in the tumor parenchyma |
| Low levels of pro-inflammatory cytokines | Elevated levels of pro-inflammatory cytokines (e.g., IFN-γ) |
| Presence of immunosuppressive cells and factors that create physical and chemical barriers | Expression of immune checkpoint molecules, reflecting active immune responses in the TME |
| TME characterized by dense stroma, aberrant vasculature, or inhibitory signaling pathways | Typically associated with robust inflammation and an immunologically engaged TME |
| Typically resistant to immune checkpoint blockade and other T cell-dependent immunotherapies | Tend to respond better to immunotherapies like immune checkpoint inhibitors due to pre-existing immune activation |
| Tumors evade immune attack largely through T cell exclusion or suppression mechanisms | Effective immune surveillance with ongoing tumor recognition and attack by immune cells |
Mechanisms Driving T Cell Exclusion in the Tumor Microenvironment
Physical Barriers Created by CAFs and ECM Remodeling
Cancer-associated fibroblasts (CAFs) generate dense extracellular matrix (ECM) components and fibrosis, creating significant physical barriers within the tumor microenvironment that hinder T cell infiltration in both human cancers and experimental mouse models. CAFs produce collagen and fibronectin, increasing stromal stiffness and establishing mechanical barriers that limit T cell migration into the tumor core. This remodeled and stiff fibrotic environment not only restricts immune cells from reaching tumor cells but also impairs T cell functions, thereby reducing effective immune surveillance and tumor cell elimination. By limiting T lymphocyte presence and activity, these structural and mechanical changes allow continued tumor growth. Importantly, remodeling the ECM to alleviate these physical barriers can improve T cell infiltration and enhance the response to checkpoint blockade therapies.
Key ECM-Mediated Mechanisms of T Cell Exclusion and Potential Therapeutic Strategies
How is a dense extracellular matrix produced in immunologically cold tumors?
- Immunosuppression – Cancer-associated fibroblasts (CAFs) produce dense ECM proteins like collagen and fibronectin, which increase stromal stiffness and create a mechanical barrier preventing T cell migration into the tumor core. Remodeling the extracellular matrix to reduce physical and mechanical barriers established by stromal cells can improve T cell infiltration and enhance the effectiveness of checkpoint blockade therapies.
- Potential therapeutic strategy – Approaches include strategies to decrease matrix stiffness, prevent collagen cross-linking, and promote ECM degradation. Both Collagenase type 1 and CCL5 have been shown to increase T cell movement out of stromal regions and into the vicinity of cancer cells. Agents such as matrix metalloproteinase inhibitors that target ECM remodeling enzymes have also shown promising results in preclinical models.
- Potential therapeutic strategy – FAP-expressing CAFs are also being targeted using antibodies, vaccines, or CAR-T cells to reduce or deplete CAFs in the tumor, thereby reducing stromal barriers and improving T cell infiltration and anti-tumor immunity.
How does stromal cell secretion of CXCL12 affect the tumor microenvironment?
- Immunosuppression – CAF-secreted CXCL12 coats T lymphocytes and excludes them in a CXCR4-dependent manner.
- Potential therapeutic strategy – CXCR4 inhibitors increase T lymphocyte numbers in the vicinity of cancer cells and improve the efficacy of anti-PD-L1 antibody treatment.
How does TGF-β signaling in the TME promote the development of immunologically cold tumors?
- Immunosuppression – TGF-β signaling contributes to ECM production, fibrosis, and immune exclusion by promoting a dense stromal barrier that physically restricts T cell infiltration. Beyond the physical barrier, TGF-β also suppresses T cell activity by modulating immune cells in the tumor microenvironment. It can promote the development and function of immunosuppressive cell types, like regulatory T cells and myeloid-derived suppressor cells, inhibit T cell proliferation and cytotoxic functions, and reduce chemokine expression needed for T cell recruitment. These effects functionally restrict T cell activity, even if T cells manage to enter the tumor.
- Potential therapeutic strategy – TGF-β inhibitors (small molecules, antibodies, or receptor traps) are being investigated to reduce ECM deposition and reprogram the TME towards a more immunopermissive state, enhancing T cell infiltration and synergizing with immune checkpoint blockade.
How does abnormal expression of adhesion molecules reduce T cell infiltration in tumors?
- Immunosuppression – Abnormal expression of adhesion molecules can reduce T cell infiltration in tumors by impairing the migration, extravasation, and retention of T cells within the tumor microenvironment, limiting effective adaptive immune responses. T cells rely on interactions with adhesion molecules such as ICAM-1, VCAM-1, and selectins expressed on tumor-associated endothelial cells to adhere to the blood vessel walls and migrate into the tumor tissue. Tumors often downregulate or aberrantly modify these adhesion molecules on the endothelium, which reduces T cell tethering, rolling, and firm adhesion, thereby limiting their extravasation from blood vessels into the tumor. Adhesion molecules also help retain T cells in the tumor stroma by mediating interactions with extracellular matrix components and stromal cells. Dysfunctional expression or altered glycosylation patterns of these molecules can reduce T cell retention, leading to poor accumulation in the tumor.
Potential therapeutic strategy – Integrins on T cells (like LFA-1 and VLA-4) bind to endothelial adhesion molecules to mediate T cell extravasation and infiltration. Abnormal regulation of these integrins, or mismatch with their ligands in tumor vessels, can hinder T cell migration. Targeting integrins (for ex. VLA-4/Integrin α4β1) can enhance both T cell extravasation across the endothelium and subsequent transit through the ECM.
Target Molecule | Role in T Cell Exclusion |
|---|---|
| ECM components that form dense stromal barriers. | |
| Fibroblast activation protein (FAP) | Serine protease that serves as a key marker of activated cancer-associated fibroblasts (CAFs) in tumors; Contributes to ECM remodeling and the formation of physical T cell barriers. |
| Fibronectin | ECM glycoprotein influencing cell adhesion and migration; Changes ECM structure and promotes tumor cell interaction with the stroma. |
| Heparanase | Enzyme that cleaves heparan sulfate proteoglycans; Remodels the ECM, potentially influencing immune cell infiltration. |
| Hyaluronan (HA) | ECM component affecting stiffness and hydration; Accumulation leads to increased interstitial pressure hindering T cell movement. |
| Collagen receptors on stromal or tumor cells; Their abnormal expression can modulate ECM stiffness and composition, impacting T cell migration. | |
| Integrin α4β1 | Expressed on stromal cells; Involved in ECM remodeling and leukocyte adhesion; Dysregulation may affect T cell trafficking and retention. |
| Integrin α5β1 | Binds fibronectin; Overexpressed on tumor or stromal cells; Can alter ECM composition, potentially limiting T cell infiltration. |
| Integrin αVβ3 | Often up-regulated in tumor-associated stromal cells and tumor vasculature; Contributes to ECM remodeling and angiogenesis, which can create barriers to T cell entry. |
| Involved in activating latent TGF-β on tumor or stromal cells, promoting ECM deposition and immune suppression, indirectly inhibiting T cell entry. | |
| Laminin | Basement membrane component; Disruption or remodeling can alter T cell migration. |
| Enzymes involved in ECM degradation and remodeling; Dysregulated activity can either facilitate or inhibit T cell entry. | |
| Podoplanin | Expressed on stromal fibroblasts; Involved in fibrotic barriers and immune suppression limiting T cell access. |
| TGF-β1 | Cytokine promoting ECM production and fibrosis; Drives CAF-mediated ECM remodeling and immunosuppression in the TME. |
Soluble Factors
Tumors secrete immunosuppressive cytokines and chemokines such as TGF-β, VEGF, and CXCL12 that contribute to T cell exclusion by inhibiting T cell migration, proliferation, and effector functions. TGF-β suppresses T cell activation, drives the development of regulatory T cells, and promotes extracellular matrix remodeling that physically hinders T cell infiltration. VEGF, primarily known for its role in angiogenesis, impairs T cell trafficking by disrupting normal vasculature development and limiting immune cell extravasation into the tumor. In addition, VEGF inhibits dendritic cell maturation, promotes the recruitment of immunosuppressive cells, and directly impairs T cell activation and function within the tumor microenvironment. CXCL12 traps T cells in stromal compartments, preventing their movement into the tumor core. Together, these soluble factors create a barrier that reduces T cell infiltration and anti-tumor activity.
Key Soluble Targets and Potential Therapeutic Strategies
How does TGF-β signaling affect anti-tumor immune responses?
- Immunosuppression – TGF-β is a potent immunosuppressive cytokine that promotes extracellular matrix production, reinforces physical barriers, and suppresses T cell infiltration and function.
- Potential therapeutic strategy – TGF-β inhibitors or TGF-β neutralizing antibodies are being tested to reduce immunosuppression and facilitate T cell penetration into tumors. Combination of TGF-β blockade with checkpoint inhibitors is under active investigation in clinical trials.
What are the effects of upregulated expression of VEGF in the tumor microenvironment?
- Immunosuppression – While the angiogenic activity of VEGF promotes the development of abnormal vasculature in tumors, thereby inhibiting T cell infiltration, VEGF also contributes to immune suppression by inhibiting dendritic cell maturation and consequently reducing T cell activation. VEGF-activated endothelial cells produce inhibitory factors such as PGE2 and Fas L, which reduce T cell infiltration and induce apoptosis. Additionally, VEGF is involved in the recruitment of immunosuppressive cells, including MDSCs and Tregs, and it also directly suppresses T cells by binding to VEGF R2, impairing their activation and tumor-killing ability.
- Potential therapeutic strategy – VEGF inhibitors (e.g., bevacizumab) combined with checkpoint blockade have demonstrated improved T cell infiltration and are approved or in trials for various cancers.
How does M-CSF inhibit anti-tumor immune responses?
- Immunosuppression – M-CSF signaling promotes recruitment and polarization of immunosuppressive tumor-associated macrophages (TAMs), which support T cell exclusion and immune evasion.
- Potential therapeutic strategy – M-CSF inhibitors are being evaluated to remodel the tumor myeloid compartment and facilitate T cell infiltration.
How can blocking CCL2 and CXCL8 pathways improve T cell infiltration in tumors?
Can targeting CXCL12-CXCR4 in tumors enhance T cell infiltration and the efficacy of anti-PD-L1 therapy?
- Immunosuppression – CAF-secreted CXCL12 coats T cells and excludes them in a CXCR4-dependent manner.
- Potential therapeutic strategy – CXCR4 inhibitors increase T cell numbers in the vicinity of cancer cells and can improve the efficacy of anti-PD-L1 antibody treatment.
Target Molecule | Role in T Cell Exclusion |
|---|---|
| Chemokines that promote the recruitment of immunosuppressive myeloid cells, which can limit T cell access and functions. | |
| CXCL12 | CAF-secreted CXCL12 coats T cells and excludes them in a CXCR4-dependent manner. |
| M-CSF | M-CSF promotes the recruitment and polarization of tumor-associated macrophages (TAMs), leading to physical and chemical barriers that limit T cell infiltration. |
| Reactive nitrogen species produced by myeloid cells that induce T cell dysfunction and apoptosis, and alter chemokine profiles and the ECM, impairing T cell tumor infiltration. | |
| PGE2 | Produced by tumor or stromal cells, suppresses effector T cells, promotes the recruitment of immunosuppressive cells (Tregs, TAMs, MDSCs), and alters chemokines and adhesion molecules to reduce T cell infiltration and function in the TME. |
| Reactive oxygen species (ROS) | Produced by tumor and immune cells, accumulates due to metabolic stress and hypoxia. Elevated ROS levels contribute to immunosuppression by inducing T cell dysfunction and apoptosis. ROS can also modify stromal components and the ECM, which may impair T cell infiltration and activity within tumors. |
| TGF-β1 | TGF-β drives CAF-mediated ECM remodeling and fibrosis in the tumor microenvironment, creating physical barriers and an immunosuppressive milieu that together promote T cell exclusion. |
| VEGF | VEGF promotes abnormal tumor vasculature that limits T cell infiltration and suppresses immunity by inhibiting dendritic cell maturation. It also promotes the expression of inhibitory factors (PGE2, Fas L) in endothelial cells, recruits immunosuppressive cells (MDSCs, Tregs), and directly suppresses T cells via VEGF R2, impairing their activation and function. |
Aberrant Chemokine Signaling
Aberrant chemokine signaling disrupts normal gradients that guide T cell migration, impairing their recruitment into tumors. Tumors and associated stromal cells can alter the production or spatial distribution of chemokines, such as CXCL9, CXCL10, and CXCL11, which are key for attracting effector T cells via CXCR3. When these chemokine gradients are diminished or skewed, T cells fail to receive proper directional cues and are unable to efficiently migrate into the tumor. As previously mentioned, tumor or surrounding stromal cells may also secrete chemokines like CXCL12 that can trap T cells in stromal areas, blocking their infiltration into the tumor core.
Key Chemokine Signaling Pathways and Potential Therapeutic Strategies
How do CXCR4 inhibitors improve T cell infiltration in tumors?
- Immunosuppression – CXCL12 produced by tumor-associated stromal cells can create a physical barrier that repels T cells or traps them in stromal regions.
- Potential therapeutic strategy – Blocking CXCL12 signaling with CXCR4 inhibitors (e.g., antagonists like AMD3100) can enhance T cell infiltration.
What are the effects of CCL2-CCR2 signaling in the tumor microenvironment?
- Immunosuppression – CCL2 recruits immunosuppressive myeloid cells and may contribute to T cell exclusion indirectly.
- Potential therapeutic strategy – CCR2 antagonists block CCL2-mediated recruitment of immunosuppressive myeloid cells, thereby modulating the tumor microenvironment to be less suppressive and more permissive for effective immune responses.
Why is CCR5 inhibition being investigated as a strategy to improve T cell infiltration in tumors?
- Immunosuppression – CCL5 can have complex roles in tumors, but is implicated in recruiting suppressive cells or altering T cell localization.
- Potential therapeutic strategy – CCR5 inhibition is being explored as a strategy to remodel the TME. This strategy aims to disrupt the recruitment and function of immunosuppressive cells, thereby reducing tumor-promoting signals and enhancing anti-tumor immune activity.
How can signaling through CXCR3 be leveraged to enhance effector T cell infiltration?
- Immune activation – Unlike the previously noted chemokines, CXCL9, CXCL10, and CXCL11 attract effector T cells into tumors through their interactions with CXCR3.
- Potential therapeutic strategy – Stimulating CXCR3 signaling or enhancing the expression of these chemokines represents a promising therapeutic strategy to improve effector T cell infiltration in tumors.
Target Chemokine | Target Receptor | Role in T Cell Exclusion |
|---|---|---|
| CCL2 | CCR2 | Involved in recruiting suppressive myeloid cells to the TME, including TAMs and MDSCs, which contribute to an immunosuppressive milieu; This environment can inhibit effector T cell infiltration and function, thereby indirectly promoting T cell exclusion from tumors. |
| CCL5 | CCR5 | Modulates immune cell trafficking; Involved in the recruitment of cytotoxic T cells, but can also recruit immunosuppressive cells such as Tregs and MDSCs, contributing to immunosuppression and indirectly supporting T cell exclusion. |
| CCR4 | Involved in recruiting CCR4-expressing regulatory T cells to the TME; Tregs suppress effector T cell functions, contributing to an immunosuppressive microenvironment that indirectly supports T cell exclusion and tumor immune evasion. | |
| CCL20 | CCR6 | Involved in recruiting CCR6-expressing regulatory T cells to the TME; Tregs suppress effector T cell functions, contributing to an immunosuppressive microenvironment that indirectly supports T cell exclusion and tumor immune evasion. |
| CX3CL1 | CX3CR1 | CX3CL1 functions as both a soluble chemokine and an adhesion molecule, attracting CX3CR1-expressing effector T cells and NK cells into tumors; Altered signaling can affect T cell and monocyte localization. |
| CXCL8 | Promotes the recruitment of neutrophils and MDSCs to the TME; High levels of CXCL8 correlate with an immunosuppressive environment and impaired T cell infiltration; CXCL8 also promotes angiogenesis and alters the ECM, which can create abnormal vasculature or physical barriers that hinder effective T cell trafficking into the tumor. | |
| CXCR3 | Involved in regulating effector T cell trafficking to tumors; High expression of these chemokines is frequently associated with increased infiltration of effector T cells and a more favorable anti-tumor immune response. | |
| CXCL12 | CXCR4 | CXCL12 produced by cancer-associated fibroblasts (CAFs) binds CXCR4 on T cells, sequestering them in stromal regions away from tumor cells; CXCL12 also acts in an autocrine loop to stimulate CAF activation, leading to increased secretion of ECM proteins and the development of a denser, more fibrotic tumor stroma. |
Metabolic Barriers
Hypoxia and nutrient depletion within the tumor microenvironment (TME) create metabolic barriers that impair T cell viability, function, and trafficking. Tumor cells and stromal cells consume large amounts of oxygen and essential nutrients such as glucose and amino acids, leading to a nutrient-poor, oxygen-deprived environment. Hypoxia stabilizes hypoxia-inducible factors (HIFs), which drive the expression of immunosuppressive factors and promote extracellular matrix remodeling, restricting T cell entry. Limited glucose availability deprives T lymphocytes of the energy required for activation, proliferation, and migration. Similarly, depletion of amino acids like arginine and tryptophan, often through increased expression of enzymes such as arginase and IDO in the TME, suppresses T cell responses and can induce T cell anergy or apoptosis. These metabolic constraints not only reduce the survival and cytotoxic capacity of CD8+ T cells, but also hinder their ability to traffic effectively into tumors, thereby contributing to immune evasion.
Key Metabolic Factors and Potential Therapeutic Strategies
What is the effect of adenosine signaling on T cell activity?
- Immunosuppression – Tumors and stromal cells produce high levels of extracellular adenosine via the ectonucleotidases, CD39 and CD73. Adenosine suppresses T cell activation and promotes T cell exclusion by signaling through the receptors, A2aR and A2bR. Activation of these receptors raises intracellular cyclic AMP (cAMP), leading to reduced T cell proliferation, cytokine production, and cytotoxic activity. Adenosine signaling can also modulate other cells in the tumor microenvironment, contributing to stromal changes and immunosuppressive cell recruitment, which collectively hinder T cell infiltration.
- Potential therapeutic strategies – CD39 inhibitors, CD73 inhibitors, and adenosine receptor inhibitors (A2A antagonists) are in clinical trials to reduce adenosine-mediated immunosuppression and enhance T cell infiltration and function.
How do hypoxic conditions in tumors affect T cell infiltration?
- Immunosuppression – Hypoxic regions in tumors drive HIF (hypoxia-inducible factor) expression, particularly HIF-1α, which promotes immunosuppressive gene programs, including upregulation of adenosine production and the recruitment of suppressive cells, which create an immunosuppressive, metabolically hostile environment limiting the infiltration and function of cytotoxic T cells. HIF-1α also directly induces VEGF (vascular endothelial growth factor) expression, leading to aberrant angiogenesis and abnormal tumor vasculature. This dysfunctional vasculature further limits the infiltration and function of cytotoxic T cells, thereby promoting tumor immune evasion.
- Potential therapeutic strategy – Drugs targeting hypoxia pathways or normalizing tumor oxygenation (e.g., HIF inhibitors, hypoxia-activated prodrugs) are being explored to relieve metabolic suppression and improve T cell access.
How does up-regulated expression of Arginase 1 in the tumor microenvironment affect T cells?
- Immunosuppression – Arginase 1 expressed by myeloid and stromal cells depletes L-arginine, an amino acid critical for T cell proliferation and function, leading to T cell suppression and exclusion.
- Potential therapeutic strategy – Arginase inhibitors are under investigation to restore arginine availability and improve immune cell infiltration.
What is the function of indoleamine 2,3-dioxygenase and how does it affect T cell activity?
- Immunosuppression – Enzymes like indoleamine 2,3-dioxygenase (IDO) break down tryptophan, producing metabolites, such as kynurenine, that inhibit T cells and promote the differentiation and expansion of regulatory T cells, supporting T cell exclusion in the tumor microenvironment.
- Potential therapeutic strategy – IDO inhibitors are being investigated to counteract this metabolic checkpoint, with combination immunotherapies.
How does lactate accumulate in the TME and how does it affect the immune response?
- Immunosuppression – High glycolytic activity in tumors leads to glucose competition and lactate buildup, which acidifies the microenvironment and impairs T cell function and infiltration.
Target Molecule | Role in T Cell Exclusion |
|---|---|
| Adenosine | Immunosuppressive metabolite in the TME that binds to A2a and A2b receptors on T cells, inhibiting their proliferation and cytokine production; It promotes the development and recruitment of immunosuppressive cells, including Tregs and MDSCs; Adenosine also alters chemokine profiles and can impact tumor vasculature and stromal cells, creating physical and biochemical barriers that limit T cell infiltration. |
| Arginase (ARG1) | Arg1 depletes L-arginine, essential for T cell proliferation and function; This nutrient-depleted environment hinders T cell survival and infiltration, contributing to exclusion. |
| Adenosine receptors that mediate signaling pathways that inhibit T cell activation, proliferation, and effector functions; Signaling through these receptors on stromal and endothelial cells within the TME leads to altered chemokine expression and changes in the tumor vasculature that collectively reduce T cell infiltration and create a more immunosuppressive environment. | |
| Carnitine palmitoyltransferase 1A (CPT1A) | Rate-limiting enzyme that transports long-chain fatty acids into mitochondria for β-oxidation; Increased fatty acid oxidation supports the metabolic programs of Tregs and exhausted T cells. This metabolic shift leads to nutrient competition that impairs T cell survival and function, and alters cytokine and chemokine secretion, thereby reducing effector T cell infiltration. |
| Ectoenzymes involved in the production of extracellular adenosine. | |
| HIF-1α | Transcription factor stabilized under hypoxic conditions that reprograms tumor cell metabolism toward glycolysis; Promotes the expression of factors involved in ECM remodeling, immunosuppression, chemokine profile alterations, and angiogenesis, collectively contributing to reduced T cell infiltration in the TME. |
| Indoleamine 2,3-dioxygenase (IDO) | Enzyme involved in tryptophan catabolism; Promotes tryptophan depletion and T cell anergy or apoptosis in the tumor microenvironment. The metabolites produced, such as kynurenine, promote Treg differentiation and MDSC activation, leading to effector T cell exclusion and dysfunction. |
| Lactate dehydrogenase A/LDHA | Enzyme that catalyzes the conversion of pyruvate to lactate, regenerating NAD+ in the process, which is crucial for sustaining glycolysis, especially under hypoxic conditions. Elevated lactate production acidifies the TME, which can impair T cell proliferation and function, and reduce motility and infiltration into the tumor. |
| Lactate transporters frequently up-regulated in highly glycolytic tumor cells; Contribute to extracellular lactate accumulation, which suppresses T cell activity and can reduce T cell infiltration in tumors. | |
| Reactive oxygen species (ROS) | Produced by tumor and immune cells, accumulates due to metabolic stress and hypoxia. Elevated ROS levels contribute to immunosuppression by inducing T cell dysfunction and apoptosis. ROS can also modify stromal components and the ECM, which may impair T cell infiltration and activity within tumors. |
Stromal and Tumor Inhibitory Immune Checkpoints
Upregulated immune checkpoint molecules, like PD-L1 expressed on tumor and stromal cells play critical roles in suppressing effective T cell activation and function within the tumor microenvironment. PD-L1 binds to PD-1 receptors on T cells, inhibiting proliferation, cytokine production, cytotoxicity, and inducing exhaustion, even in the presence of tumor antigen recognition. This and other immune checkpoint pathways establish an immunosuppressive environment that contributes to limited T cell infiltration, allowing tumors to evade immune destruction.
Growing evidence suggests that combining immune checkpoint blockade with strategies that remodel the tumor stroma can synergistically enhance T cell infiltration and activation. Stromal components often contribute to immune suppression and T cell exclusion by creating immunosuppressive niches. By addressing both immune checkpoints and the stromal environment simultaneously, these combinatorial approaches aim to dismantle multiple layers of immune resistance. Such dual targeting may improve clinical outcomes by restoring effective anti-tumor immunity where single treatments have limited success.
Key Checkpoint Targets and Potential Therapeutic Strategies
What combinatorial strategies targeting stromal cells are being actively investigated?
- Immunosuppression – Stromal cells contribute to local immune suppression not only by expressing checkpoint ligands, but also through their enzymatic activities and physical remodeling of the tumor microenvironment. Combinatorial strategies targeting stromal cells directly, blocking their inhibitory ligands, and remodeling the physical barrier formed by these cells may help alleviate T cell exclusion.
- Potential therapeutic strategy – Combining immune checkpoint inhibitors (ICIs; e.g., anti-PD-1, anti-PD-L1) with agents targeting stromal cell populations or specifically their enzymatic functions can disrupt tumor-promoting barriers and enhance T cell infiltration. Approaches include inhibiting activated CAFs via fibroblast activation protein (FAP) or targeting stromal subsets, such as LRRC15-expressing CAFs, as well as using MMP inhibitors to block MMPs produced by stromal cells that contribute to immune exclusion through microenvironmental remodeling. By modulating stromal cell functions and their immunosuppressive activities, these strategies aim to synergistically enhance anti-tumor immunity. Notably, FAP inhibitors combined with ICIs are currently in early clinical trials, and LRRC15-directed therapies (antibody-drug conjugates) designed to deplete stromal cells and remodel the immunosuppressive stroma are also under investigation.
- Potential therapeutic strategy – Blocking checkpoint ligands expressed explicitly by stromal cells could further alleviate T cell suppression. While most checkpoint inhibitors target tumor or immune cells broadly, newer biologics (e.g., bispecific antibodies that can simultaneously bind a stromal marker and an immune checkpoint ligand) or targeted delivery platforms are being developed to improve specificity and efficacy against stromal cell-expressed immune checkpoint ligands.
Target Molecule | Role in T Cell Exclusion |
|---|---|
| B7 family proteins that Inhibit T cell activation and function; Contribute to immune evasion and T cell exclusion by suppressing effector T cell responses. | |
| CD73 | Ectoenzyme involved in the production of extracellular adenosine, which inhibits T cell activity and infiltration. |
| Ligands that bind to TIGIT on T cells and natural killer (NK) cells, inhibiting their activity. | |
| FAP | Serine protease that serves as a key marker of activated cancer-associated fibroblasts (CAFs) in tumors; Contributes to ECM remodeling and formation of physical T cell barriers. |
| Galectin-9 | Ligand that binds to TIM-3 on T cells; Induces T cell apoptosis and exhaustion, leading to reduced T cell infiltration in tumors. |
| Indoleamine 2,3-dioxygenase (IDO) | Enzyme involved in tryptophan catabolism; Promotes tryptophan depletion and T cell anergy or apoptosis in the tumor microenvironment. The metabolites produced, such as kynurenine, promote Treg differentiation and MDSC activation, leading to effector T cell exclusion and dysfunction. |
| LRRC15 | Expressed by activated stromal fibroblasts; Contributes to stromal barriers and immune suppression. |
| Immune checkpoint molecules that bind to the PD-1 receptor on T cells, inhibiting their activation and promoting T cell exhaustion and exclusion from tumor sites. | |
| VISTA/B7-H5 | B7 family protein that suppresses T cell activation and cytokine production; Promotes T cell dysfunction and exclusion in the TME. |
Suppressive Cell Populations
Regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs) are key immunosuppressive cell populations that shape the tumor microenvironment to inhibit effective T cell infiltration and function. Cancer research has increasingly focused on understanding how these cells contribute to immune suppression.
- Tregs: CD4+CD25+FoxP3+ T lymphocytes that suppress immune responses by producing inhibitory cytokines like IL-10 and TGF-β to directly suppress effector T cell activation and proliferation.
- MDSCs: Immature myeloid cells that accumulate in tumors and produce factors such as arginase, nitric oxide, and reactive oxygen species, which impair T cell receptor signaling and promote T cell dysfunction.
- TAMs: Typically polarized towards an M2-like phenotype, TAMs secrete anti-inflammatory cytokines, promote tissue remodeling, and express immune checkpoint ligands that collectively suppress T cell activity.
Together, these suppressive cells create a hostile and immunosuppressive environment that prevents T cell infiltration, reduces their anti-tumor activity, and facilitates tumor immune evasion.
Key Suppressive Cell Populations and Potential Therapeutic Strategies
What therapeutic strategies are being investigated to overcome the obstacle that MDSCs present in the TME?
- Immunosuppression – Myeloid-derived suppressor cells (MDSCs) suppress T cell activation and infiltration through the production of reactive oxygen species, arginase, and immunosuppressive cytokines (e.g., IL-10, TGF-β).
- Potential therapeutic strategies
- Inhibition of MDSC recruitment and trafficking using antagonists of CXCR2, CCR2, or CXCR4.
- Induction of MDSC differentiation with agents like all-trans retinoic acid (ATRA)
- Inhibition of MDSC immunosuppressive functions by targeting enzymes like ARG1 and iNOS with PDE5 inhibitors
- Depletion of MDSCs using chemotherapeutics (e.g., gemcitabine, 5-fluorouracil) at low doses or antibodies targeting surface markers to reduce MDSC numbers
- Blocking MDSC expansion signals by inhibiting tumor-derived factors such as GM-CSF, G-CSF, IL-6, M-CSF, and VEGF that promote MDSC proliferation and survival
- Potential therapeutic strategies
What strategies can be used to target regulatory T cells and enhance anti-tumor immune responses?
- Immunosuppression – Regulatory T cells (Tregs) suppress effector T cell function via the production of immunosuppressive cytokines (IL-10, TGF-β) and metabolic disruption.
- Potential therapeutic strategies
- Anti-CTLA-4 antibodies to deplete intratumoral Tregs via ADCC
- Depletion of Tregs using anti-CD25 or anti-CCR4 antibodies
- Inhibition of Treg immunosuppressive functions (e.g., targeting CTLA-4, LAG-3, or TIGIT) or survival (e.g., PI3K-δ inhibitors)
- Targeting IL-2 signaling to preferentially promote effector T cells over Tregs by using altered IL-2 or IL-2 receptor agonists/antagonists
- Low dose chemotherapy to preferentially deplete Tregs, reducing immunosuppression
- Potential therapeutic strategies
How can tumor-associated macrophages be targeted to improve T cell infiltration in tumors?
- Immunosuppression – M2-polarized tumor-associated macrophages (TAMs) secrete factors (e.g., IL-10, TGF-β, VEGF) that promote immunosuppression and physical barriers to T cell infiltration.
- Potential therapeutic strategies
- Depletion of TAMs using anti-M-CSF R antibodies can reduce TAM numbers in tumors
- Inhibition of TAM recruitment by blocking pathways like CCL2-CCR2 and M-CSF-M-CSF R to prevent monocyte recruitment and differentiation into TAMs
- Reprogramming TAM polarization by shifting from a pro-tumoral M2 phenotype to an anti-tumoral M1 phenotype with agents like CD40 agonists, TLR agonists, or PI-3Kγ inhibitors
- Inhibition of TAM-mediated immunosuppression targeting secreted molecules such as IL-10 or TGF-β, or immune checkpoint ligands like PD-L1
- Inhibition of TAM metabolic pathways by targeting Arginase 1 or IDO
- Using TAMs as drug delivery vehicles to deliver anti-cancer agents directly within the TME
- Potential therapeutic strategies
Target Molecule | Cell Type | Role in T Cell Exclusion |
|---|---|---|
| Arginase 1 | MDSCs, TAMs | Enzyme involved in the metabolism of L-arginine; Depletes L-arginine, limiting T cell function. |
| CD11b | MDSCs, TAMs | Cell surface marker commonly used to identify and isolate cells of the myeloid lineage; Used in combination with other markers to identify MDSCs and TAMs. |
| CD15 | MDSCs | Cell surface marker commonly used to distinguish human granulocytic MDSCs from monocytic MDSCs. |
| CD25/IL-2 Rα | Tregs | Cell surface marker on active Tregs; Mediates growth and survival. |
| CD66b | MDSCs | Cell surface marker commonly used to distinguish human granulocytic MDSCs from monocytic MDSCs. |
| TAMs | Markers of M2 macrophages; Associated with an immunosuppressive macrophage phenotype. | |
| FoxP3 | Tregs | Master transcriptional regulator required for Treg development and suppressive activity. |
| Indoleamine 2,3-dioxygenase (IDO) | MDSCs, TAMs | Enzyme involved in tryptophan catabolism, leading to tryptophan depletion and T cell anergy or apoptosis. The metabolites produced, such as kynurenine, promote Treg differentiation and MDSC activation, leading to effector T cell exclusion and dysfunction. |
| MDSCs | Cell surface markers commonly used to distinguish granulocytic (Ly-6C-Ly-6G+) and monocytic (Ly-6C+Ly-6G-/low) MDSC subtypes in mice. | |
| M-CSF R/CD115 | TAMs | Cell surface receptor for M-CSF; Regulates macrophage survival and suppressive functions. |
Dysfunctional Vasculature
Tumor blood vessels are often abnormal, disorganized, and leaky, causing inefficient blood flow and hypoxic regions within the tumor microenvironment. This dysfunctional vasculature creates multiple barriers to T cell infiltration, including:
- Physical barrier: Abnormal endothelial cells and a disorganized vessel network physically hinder T cells from exiting the bloodstream and entering tumor tissue.
- Adhesion molecule downregulation: Tumor endothelial cells often downregulate adhesion molecules such as ICAM-1 and VCAM-1, which are essential for T cell attachment and transmigration.
- Immunosuppressive signaling: The hypoxic environment and tumor-derived factors promote the expression of immunosuppressive molecules like PD-L1 and Fas ligand on endothelial cells, inhibiting T cell infiltration and inducing T cell apoptosis.
- Abnormal chemokine gradients: Dysfunctional vasculature disrupts normal chemokine gradients that guide T cells, thereby misdirecting their migration and limiting their entry into tumors.
Together, these factors ensure robust T cell exclusion from the tumor microenvironment.
Key Vascular Targets and Potential Therapeutic Strategies
How can targeting VEGF to normalize tumor vasculature enhance T cell infiltration and improve immunotherapy outcomes?
- Immunosuppression – Aberrant tumor vasculature is structurally irregular and functionally abnormal, limiting T cell trafficking into tumors.
- Potential therapeutic strategy – Vascular endothelial growth factor (VEGF) is a key protein that drives angiogenesis or the formation or new blood vessels within tumors. While angiogenesis is essential for tumor growth by supplying oxygen and nutrients, the vasculature formed under the influence of VEGF is often structurally abnormal and functionally inefficient. This aberrant vasculature is characterized by irregular, tortuous, and leaky blood vessels, which result in poor perfusion and hypoxic regions within the tumor. These conditions create physical and biochemical barriers that impede effective trafficking and extravasation of cytotoxic T cells into the tumor parenchyma, thereby limiting anti-tumor immune responses. Anti-VEGF therapies aim to normalize the tumor vasculature, improving vessel perfusion and T cell extravasation. This vascular normalization can enhance responses to immunotherapy. VEGF inhibitors (e.g., bevacizumab) combined with checkpoint blockade have demonstrated improved T cell infiltration and are either approved or in clinical trials for various cancer types.
How does Angiopoietin-2/Tie2 signaling contribute to tumor vascular dysfunction and immunosuppression?
- Immunosuppression – Aberrant tumor vasculature is structurally irregular and functionally abnormal, limiting T cell trafficking into tumors.
- Potential therapeutic strategy – Abnormal angiopoietin signaling (particularly Ang-2) contributes to dysfunctional, leaky vessels that impair T cell access. Targeting Ang-2 by inhibition or activating the Tie-2 receptor can promote vessel normalization and enhance T cell infiltration. Conversely, Tie2 antagonists (e.g., trebananib) have been evaluated in clinical trials to inhibit tumor angiogenesis, both alone and in combination with immune checkpoint inhibitors. These agents aim to remodel or prune tumor vessels to disrupt abnormal angiogenesis, which may modulate the tumor microenvironment and potentially enhance T cell infiltration and the efficacy of immunotherapies. However, the effects on vessel normalization and immune cell infiltration can be variable and context-dependent.
How does VE-PTP inhibition influence Tie2 signaling and the tumor vasculature?
- Immunosuppression – Aberrant tumor vasculature is structurally irregular and functionally abnormal, limiting T cell trafficking into tumors.
- Potential therapeutic strategy – Vascular Endothelial Protein Tyrosine Phosphatase (VE-PTP) negatively regulates Tie2, so inhibiting VE-PTP enhances Tie2 signaling, improving vascular stability and perfusion, which may improve T cell entry into tumors. Agents targeting VE-PTP, such as AKB-9778, have progressed to clinical trials aiming to improve vascular stability and immune cell infiltration by activating Tie2.
Are adhesion molecules such as ICAM-1 and VCAM-1 being targeted to improve T cell trafficking in tumors?
- Immunosuppression – Aberrant tumor vasculature is structurally irregular and functionally abnormal, limiting T cell trafficking into tumors.
- Potential therapeutic strategy – Abnormal vasculature often downregulates adhesion molecules like ICAM-1 and VCAM-1 that are essential for T cell extravasation. Strategies to increase the expression or function of these molecules can facilitate T cell trafficking across the endothelium. While direct targeting of ICAM-1 or VCAM-1 is less common clinically, research is ongoing to understand how to modulate their expression via cytokines or epigenetic regulators to improve immune cell trafficking.
How do immune checkpoint molecules on tumor endothelial cells contribute to T cell exclusion and immunosuppression in the TME?
- Immunosuppression – Aberrant tumor vasculature is structurally irregular and functionally abnormal, limiting T cell trafficking into tumors.
- Potential therapeutic strategy – Tumor endothelial cells can express immune checkpoint molecules (e.g., PD-L1, Fas L) that inhibit T cell function or induce T cell apoptosis. Blocking these pathways may prevent immune exclusion. Studies have identified PD-L1 and Fas L expression on tumor endothelium as barriers to immunity, and combination therapies that target both immune checkpoints on tumor and endothelial cells are being explored.
How does abnormal metabolism in tumor endothelial cells impact vessel function and T cell infiltration?
- Immunosuppression – Aberrant tumor vasculature is structurally irregular and functionally abnormal, limiting T cell trafficking into tumors.
- Potential therapeutic strategy – Abnormal metabolism in tumor endothelial cells, such as increased glycolysis and fatty acid oxidation, leads to dysfunctional and irregular blood vessels. These metabolic alterations impair vessel function, which in turn limits the infiltration of T cells into tumors. By targeting and modulating these metabolic pathways, it is possible to normalize the tumor vasculature, improve vessel function, and ultimately enhance T cell trafficking and immune infiltration into the tumor microenvironment.
How does improper pericyte coverage contribute to abnormal tumor vasculature and what therapeutic approaches are being investigated to improve pericyte coverage?
- Immunosuppression – Aberrant tumor vasculature is structurally irregular and functionally abnormal, limiting T cell trafficking into tumors.
- Potential therapeutic strategy – Improper pericyte coverage leads to vessel leakiness and abnormal flow. Therapeutic approaches that promote or stabilize pericyte function, though mostly in preclinical or early clinical stages, are promising strategies to improve vascular integrity and enhance T cell infiltration. These approaches include: Developing agents that enhance pericyte coverage around tumor blood vessels to reduce vessel leakiness and normalize blood flow; using drugs or biologics that support pericyte recruitment, survival, or contractility to strengthen vessel structure; and exploring treatments that modulate signaling pathways involved in pericyte-endothelial cell interactions, such as PDGF-B/PDGF Rβ signaling.
Target Molecule | Role in T Cell Exclusion |
|---|---|
| Angiopoietin-2 | Regulates blood vessel remodeling and stabilization in a context-dependent manner; Promotes vascular leakage and impaired T cell trafficking. |
| Endothelin-1 | Vasconstrictor peptide affecting blood flow; Contributes to hypoxia and vascular abnormalities limiting T cell access. |
| ICAM-1 | Adhesion molecule on endothelial cells; Facilitates T cell transmigration; Downregulated in dysfunctional vessels. |
| PDGF Rβ | Regulates pericyte recruitment to support vessel integrity; Pericyte loss leads to poor vessel function and T cell exclusion. |
| VEGF | Key pro-angiogenic factor that promotes abnormal vessel growth in tumors; Induces irregular, leaky vasculature that hinders T cell infiltration. |
| VEGF R2 | Primary receptor mediating VEGF-driven angiogenesis; Drives dysfunctional blood vessel formation and T cell exclusion. |
A Look Inside a Tumor Wall Poster
The tumor microenvironment (TME) plays a central role in inhibiting anti-tumor immune responses. Request this poster to learn about the key mechanisms by which Tregs, MDSCs, TAMs, and tumor-derived exosomes promote immunosuppression in the tumor microenvironment.
Immune Checkpoint Targets Wall Poster
Decorate your lab with our recent poster showing the immune checkpoint ligand-receptor interactions being investigated as potential targets for cancer immunotherapy. It serves as a great reference tool and is sure to brighten up your lab.
T Cell-Based Therapies eBook
Gain essential insights into overcoming therapeutic challenges posed by the tumor microenvironment. This eBook provides a look at the biological obstacles and manufacturing complexities shaping the future of T cell therapies and solutions to accelerate advancements in the field.